[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"ac4afb38-f9f0-4fe8-a6ec-8ae6a59cd318","acronym":"A041703","url":"https://clinicaltrials.gov/study/NCT03739814","created_at":"2021-01-18T18:19:08.468Z","updated_at":"2025-02-25T12:27:03.899Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03739814 - A041703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 positive","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-24"},{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2025-02-25T13:39:22.892Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-21"},{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"5a4c3655-9f33-4faa-a284-8b91e071174d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03610971","created_at":"2022-04-24T08:59:34.197Z","updated_at":"2025-02-25T14:01:30.574Z","phase":"Phase 2","brief_title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT03610971","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-19"},{"id":"39a3ce34-fc3f-4772-a312-5b10b9a2eacf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00390793","created_at":"2022-04-24T08:54:27.800Z","updated_at":"2025-02-25T14:06:37.175Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT00390793","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 09/28/2006","start_date":" 09/28/2006","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2025-02-17"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"463898f9-d0f2-4eeb-ad5a-ad7d4f465a1f","acronym":"ASC4MORE","url":"https://clinicaltrials.gov/study/NCT03578367","created_at":"2021-01-18T17:36:31.183Z","updated_at":"2025-02-25T14:39:57.704Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","source_id_and_acronym":"NCT03578367 - ASC4MORE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 02/27/2025","study_completion_date":" 02/27/2025","last_update_posted":"2025-02-14"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"4031ba62-5860-47d7-91f9-d7064a25a760","acronym":"","url":"https://clinicaltrials.gov/study/NCT04795427","created_at":"2021-03-12T15:52:52.806Z","updated_at":"2025-02-25T15:12:00.303Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT04795427","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 05/29/2023","primary_completion_date":" 05/29/2023","study_txt":" Completion: 11/18/2024","study_completion_date":" 11/18/2024","last_update_posted":"2025-02-13"},{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"f87d503c-9d3e-4533-b224-78463c794166","acronym":"","url":"https://clinicaltrials.gov/study/NCT03817398","created_at":"2021-01-18T18:51:39.221Z","updated_at":"2025-02-25T14:51:19.717Z","phase":"Phase 2","brief_title":"Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03817398","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 11/08/2019","start_date":" 11/08/2019","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-13"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"0dfdbda7-3ab9-4117-8538-4a9b1997b0a3","acronym":"NCI-2018-00936","url":"https://clinicaltrials.gov/study/NCT03441061","created_at":"2021-01-18T16:58:19.322Z","updated_at":"2025-02-25T16:37:03.930Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease","source_id_and_acronym":"NCT03441061 - NCI-2018-00936","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/15/2018","start_date":" 02/15/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-06"},{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"fdf62ac7-f79d-46b1-9a07-c4ce7608d067","acronym":"Ascembl","url":"https://clinicaltrials.gov/study/NCT03106779","created_at":"2021-01-17T17:34:34.885Z","updated_at":"2025-02-25T16:36:53.037Z","phase":"Phase 3","brief_title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","source_id_and_acronym":"NCT03106779 - Ascembl","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-06"},{"id":"1fb9a843-c4ef-444b-994a-39091f7c4fca","acronym":"ENESTop","url":"https://clinicaltrials.gov/study/NCT01698905","created_at":"2021-01-19T06:04:36.924Z","updated_at":"2025-02-25T17:35:30.294Z","phase":"Phase 2","brief_title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","source_id_and_acronym":"NCT01698905 - ENESTop","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 163","initiation":"Initiation: 12/20/2012","start_date":" 12/20/2012","primary_txt":" Primary completion: 11/26/2015","primary_completion_date":" 11/26/2015","study_txt":" Completion: 01/19/2025","study_completion_date":" 01/19/2025","last_update_posted":"2025-01-29"},{"id":"8ee6a642-903b-4775-8ffb-3149fa1ecff5","acronym":"ENESTFreedom","url":"https://clinicaltrials.gov/study/NCT01784068","created_at":"2021-01-17T17:35:07.021Z","updated_at":"2025-02-25T17:35:31.954Z","phase":"Phase 2","brief_title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","source_id_and_acronym":"NCT01784068 - ENESTFreedom","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 Y253H","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 Y253H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 03/04/2013","start_date":" 03/04/2013","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-01-29"},{"id":"91bc7864-fd10-46ec-b629-e98e5ba03f9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06773936","created_at":"2025-02-25T15:46:10.278Z","updated_at":"2025-02-25T15:46:10.278Z","phase":"Phase 2","brief_title":"Adding Asciminib to Usual Treatment for Adults with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06773936","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2025-01-14"},{"id":"e17fb339-f241-4fee-96fe-598ffffcf271","acronym":"ASC4REAL","url":"https://clinicaltrials.gov/study/NCT06684964","created_at":"2025-02-26T07:06:31.325Z","updated_at":"2025-02-26T07:06:31.325Z","phase":"","brief_title":"RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)","source_id_and_acronym":"NCT06684964 - ASC4REAL","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-01-10"},{"id":"0adc2fbc-6b3e-4f34-8de8-ac2947fe1dfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070499","created_at":"2021-01-18T00:10:44.565Z","updated_at":"2025-02-25T16:21:43.510Z","phase":"Phase 2","brief_title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00070499","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 08/15/2004","start_date":" 08/15/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-12-27"}]